Key Events This Week
1 June: Downgrade to Strong Sell announced
2 June: Valuation metrics signal elevated risk
5 June: Week closes at Rs.0.26 (-10.34%)
1 June: Downgrade to Strong Sell Reflects Financial and Technical Weakness
Welcure Drugs & Pharmaceuticals Ltd was downgraded from 'Sell' to 'Strong Sell' by MarketsMOJO on 1 June 2026, reflecting a significant deterioration in its financial performance and technical outlook. The downgrade followed a quarterly report showing flat financial results for the period ending March 2026, with a net loss of ₹49.86 crores, representing a 663.2% decline compared to the previous four-quarter average.
Despite a 40.69% increase in net sales to ₹65.62 crores over nine months, profitability metrics worsened sharply. Operating losses were substantial, with negative EBITDA of ₹-7.4 crores and negative returns on capital employed at -7.68%. The company’s earnings per share plunged to ₹-0.40, underscoring its inability to generate profits amid rising revenues.
Technically, the stock exhibited bearish momentum, trading near its 52-week low of Rs.0.23. Indicators such as the Relative Strength Index and Bollinger Bands signalled sustained downward pressure. The stock price closed at Rs.0.28 on 1 June, down 3.45% on the day, underperforming the Sensex’s 0.96% decline.
2 June: Valuation Metrics Signal Elevated Risk Amid Market Underperformance
On 2 June, further concerns emerged as valuation metrics deteriorated, shifting the company’s grade from “very attractive” to “risky.” The price-to-earnings ratio stood at a low 0.98, but this was driven by negative earnings rather than undervaluation. Enterprise value to EBITDA and EBIT ratios were deeply negative at approximately -4.6, reflecting operational losses.
The price-to-book value ratio of 0.36, while low, was overshadowed by the company’s weak asset quality and profitability concerns. Compared to sector peers such as Bliss GVS Pharma and Kwality Pharma, which trade at P/E ratios above 30 and positive EV/EBITDA multiples, Welcure’s valuation metrics highlighted its precarious position.
The stock price declined further to Rs.0.27, down 3.57% on the day, while the Sensex gained 0.43%. Trading volumes were subdued, indicating limited investor interest amid growing risk perceptions.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
3 June to 5 June: Continued Price Decline Amid Mixed Market Movements
The stock continued its downward trajectory on 3 June, closing at Rs.0.26, down 3.70% on the day, while the Sensex declined 0.34%. Despite a large volume spike on 4 June with nearly 13 million shares traded, the stock price remained flat at Rs.0.26, even as the Sensex gained 0.19%. This stagnation amid increased trading volume suggests persistent selling pressure or lack of buying interest.
On 5 June, the stock price held steady at Rs.0.26, with no change from the previous day, while the Sensex slipped 0.10%. The week closed with a 10.34% loss for Welcure Drugs, markedly underperforming the Sensex’s 0.78% decline, underscoring the stock’s weak momentum and investor sentiment.
Holding Welcure Drugs & Pharmaceuticals Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-01 | Rs.0.28 | -3.45% | 35,077.62 | -0.96% |
| 2026-06-02 | Rs.0.27 | -3.57% | 35,227.64 | +0.43% |
| 2026-06-03 | Rs.0.26 | -3.70% | 35,107.33 | -0.34% |
| 2026-06-04 | Rs.0.26 | +0.00% | 35,175.61 | +0.19% |
| 2026-06-05 | Rs.0.26 | +0.00% | 35,141.95 | -0.10% |
Key Takeaways
Financial deterioration: Despite revenue growth of 40.69% over nine months, Welcure Drugs posted a significant quarterly net loss of ₹49.86 crores, with negative EBITDA and poor capital efficiency, signalling operational challenges.
Valuation concerns: The downgrade from “very attractive” to “risky” valuation reflects negative earnings and weak asset quality. The company’s P/E ratio of 0.98 is misleading due to losses, while EV/EBITDA and EV/EBIT ratios remain deeply negative.
Technical weakness: Bearish momentum persisted throughout the week, with the stock trading near its 52-week low and underperforming the Sensex by a wide margin.
Market underperformance: The stock declined 10.34% over the week, compared to the Sensex’s 0.78% fall, highlighting investor caution amid deteriorating fundamentals.
Liquidity and volatility: Trading volumes fluctuated, with a notable spike on 4 June that did not translate into price gains, indicating selling pressure or lack of buying interest.
Conclusion
Welcure Drugs & Pharmaceuticals Ltd faced a difficult week marked by a downgrade to a 'Strong Sell' rating and a shift in valuation to a risky profile. The company’s financial results reveal significant losses despite revenue growth, while technical indicators confirm bearish momentum. The stock’s steep decline of 10.34% against a modest Sensex fall underscores the challenges it faces in regaining investor confidence.
Given the negative operational earnings, poor capital returns, and valuation concerns, the stock remains under pressure. Investors should note the substantial underperformance relative to sector peers and benchmark indices. The current environment suggests that Welcure Drugs will require significant operational improvements to reverse its downward trend and restore valuation appeal.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
